Clinical trialUNITERAREApr 5
Researchers are testing a drug called baricitinib to see if it is safe and works well for patients with Job syndrome who also have lupus-like disease and/or atopic dermatitis (severe itchy skin). Job syndrome is a rare immune system disorder that makes it hard for the body to fight infections and causes skin problems. This is an early-stage study that will check for side effects and how well the drug works.
WHY IT MATTERSThis Phase 1 trial is now actively recruiting patients with Job syndrome complicated by lupus-like disease and/or atopic dermatitis — a rare combination that has limited treatment options and is being studied by the National Institute of Allergy and Infectious Diseases.
ResearchBIORXIVApr 5
Scientists created a new tool called Gene Portals that helps doctors understand whether genetic changes cause rare diseases. Instead of searching through many different websites and databases, doctors can now use one central location that combines patient information, lab test results, and genetic data all in one place. This makes it easier and faster to figure out if a genetic mutation is actually responsible for a patient's rare disease.
WHY IT MATTERSPatients with rare genetic diseases may finally get faster and more accurate diagnoses because doctors will have a standardized way to interpret genetic test results, reducing the chance of misdiagnosis or missed diagnoses.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance fund for ALS (a disease that affects nerve cells controlling muscles) is currently closed and not accepting new applications. This fund previously provided up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have ALS and were counting on this $12,000 annual assistance from PAN Foundation, you'll need to explore other financial resources immediately, as this fund is no longer available.
Clinical trialUNITERAREApr 3
Researchers at King's College London are testing whether probiotics (helpful bacteria) can reduce skin inflammation that some people experience during perimenopause (the years leading up to menopause). This is an early-stage study to see if this approach might work before larger trials are done. The study is now accepting participants.
WHY IT MATTERSIf probiotics prove effective for perimenopause-related skin inflammation, this could offer a non-hormonal treatment option for people experiencing this symptom during the menopausal transition.
Clinical trialUNITERAREApr 3
Researchers are looking for patients who need a procedure called a transjugular intrahepatic portosystemic shunt (TIPS) to help study how blood clotting works in patients with liver disease. This trial will examine blood clotting patterns before and after the procedure to better understand how TIPS affects the body's ability to form and break down blood clots. The study is recruiting patients starting in April 2026 and is being run by hospitals in Paris.
WHY IT MATTERSThis trial is now recruiting patients undergoing TIPS placement — if you have advanced liver disease with portal hypertension and are scheduled for this procedure, you may be eligible to contribute to research that could improve how doctors manage bleeding risks in liver disease patients.
Drug approvalOPENFDAApr 3
The FDA has approved a new drug made by TEVA PHARMACEUTICALS, but the article doesn't say what disease it treats or what the drug is called. This approval means the drug is now available for patients, but we need more information to understand who might benefit from it.
WHY IT MATTERSWe cannot determine the specific impact on patients because the drug name and indication are not disclosed in this announcement.
Clinical trialCLINICALTRIALSApr 1
Researchers are looking for 3,100 people to join a study about why patients don't take their medications as prescribed. The study will test a new approach to help people stick to their treatment plans, which could improve their health and reduce unnecessary hospital visits. About half of all patients don't take their medicines the right way, and this problem gets worse when treatment also requires lifestyle changes.
WHY IT MATTERSThis trial directly addresses medication non-adherence across multiple rare disease categories, meaning patients with rare conditions could benefit from proven strategies to better manage their treatments and health outcomes.
ResearchCONGRESSApr 1
Researchers studied how life circumstances like poverty, access to healthcare, and education affect children with developmental delays and intellectual disabilities. They also looked at how long it takes families to get a diagnosis and whether genetic testing helps. The study suggests that where you live and your resources matter a lot in getting answers for why a child has developmental challenges.
WHY IT MATTERSThis research highlights that children from disadvantaged backgrounds face longer diagnostic journeys for developmental delays—meaning families may wait years longer to understand their child's condition and access support services.
ResearchPUBMEDApr 1
Researchers reviewed 78 studies about early satiety (feeling full quickly after eating small amounts) in cancer patients. They found this symptom is common but often overlooked, and doctors don't have consistent ways to measure or describe it. The review shows there are big gaps in how we understand and treat this problem for cancer patients.
WHY IT MATTERSEarly satiety causes cancer patients to eat less and lose weight, which can weaken their ability to fight cancer and recover from treatment—but doctors rarely screen for or address this specific symptom.
ResearchBIORXIVMar 30
Researchers are testing whether artificial intelligence programs called large language models can help doctors decide which genetic tests to order for patients with rare diseases. Instead of doctors having to memorize complicated guidelines, the AI could read the patient's information and recommend whether a simple gene panel or a more complete genetic test would be best. This could make the process faster and more consistent across different hospitals.
WHY IT MATTERSIf this AI tool works well, patients with rare diseases could get the right genetic test recommended faster, potentially leading to quicker diagnoses and treatment decisions.
ResearchPUBMEDMar 28
Scientists are getting better at finding rare genetic diseases using a tool called next-generation sequencing, which can read a person's DNA quickly and accurately. They're also developing new medicines called antisense oligonucleotides that can be customized for each patient to fix problems caused by genetic mutations. Together, these advances mean doctors can diagnose rare diseases faster and create personalized treatments tailored to each person's specific genetic makeup.
WHY IT MATTERSThis research shows a clear path for patients with rare genetic diseases to move from diagnosis to personalized treatment within a single medical framework, potentially reducing the diagnostic odyssey that currently takes years for many rare disease patients.